A 4-year-old boy from Tamil Nadu presents with severe hemolytic anemia (Hb 6.5 g/dL), hepatosplenomegaly, and bone deformities. Peripheral blood smear shows target cells, nucleated RBCs, and polychromasia. Hemoglobin electrophoresis reveals absent HbA and elevated HbF (80%) and HbA2 (18%). The child requires transfusions every 3–4 weeks. His HLA-matched sibling is available. What is the most appropriate next step in management?

Explanation

## Clinical Context This is a case of **β-thalassemia major** (TM) with: - Severe hemolytic anemia requiring regular transfusions - Absent HbA (homozygous β-globin mutation) - Elevated HbF and HbA2 (diagnostic pattern) - Young age (4 years) with an HLA-matched sibling donor ## Management Strategy for β-Thalassemia Major **Key Point:** The only curative therapy for β-thalassemia major is allogeneic HSCT, particularly when performed early in life with an HLA-matched sibling donor. ### Indications for HSCT in β-TM | Factor | Significance | |--------|---------------| | **Age at transplant** | <16 years: better outcomes; <6 years: >90% disease-free survival | | **Donor type** | HLA-matched sibling: gold standard (80–90% cure rate) | | **Disease burden** | Early transplant (before iron overload, organ damage) improves outcomes | | **Chelation status** | Patients already on iron chelation have worse transplant outcomes | **High-Yield:** The Pesaro risk stratification for β-TM HSCT uses: age, ferritin level, and hepatomegaly. This patient has an excellent window for transplant—young age, available matched sibling, and not yet heavily iron-loaded. ## Why This Is the Next Step 1. **Curative potential:** HSCT is the only therapy that corrects the underlying genetic defect. 2. **Optimal timing:** Age <6 years with matched sibling donor offers >90% disease-free survival. 3. **Prevent complications:** Early transplant avoids secondary iron overload, cardiac dysfunction, endocrine failure, and cirrhosis. 4. **Current standard of care:** All major guidelines (EBMT, NCCN, Indian hematology societies) recommend HSCT as first-line curative therapy in this scenario. **Clinical Pearl:** Delaying HSCT to initiate chelation therapy is counterproductive—iron overload itself worsens transplant outcomes and increases transplant-related mortality. ## Post-HSCT Monitoring - Engraftment assessment (day +14–28) - Chimerism studies - GVHD prophylaxis and monitoring - Immune reconstitution assessment [cite:Robbins 10e Ch 14]